Compare TCRX & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCRX | EQS |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 12.3M |
| IPO Year | 2021 | 1995 |
| Metric | TCRX | EQS |
|---|---|---|
| Price | $0.14 | $0.56 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 420.2K | 7.6K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.14 | $0.53 |
| 52 Week High | $1.47 | $2.05 |
| Indicator | TCRX | EQS |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 43.24 |
| Support Level | N/A | N/A |
| Resistance Level | $0.21 | $1.05 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 8.07 | 34.99 |
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.